
Plenary Session
1.09 Response Rate in Phase I trials, JACOB, and MI, Stroke, and Metastasis as Hard Endpoints
34 min•20 september 2018
Om avsnittet
Special episode! We discuss the recent correspondence in NEJM on response rate in phase I clinical trials, the JACOB trial published in The Lancet Oncology on pertuzumab for HER2-positive gastric cancer, and we give an evaluation of MI, stroke, and metastasis as hard endpoints.
Fler avsnitt
Visa alla avsnitt av Plenary SessionPlenary Session med Vinay Prasad, MD MPH finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.